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A B S T R A C T
Being of the most frequent causes of insomnia, which in the end leads to chronic fatigue, inadequate performance of
daily activities, and serious disruption of quality of living, restless legs syndrome (RLS) is nowadays not only a serious
medical problem but a socio-economical one as well. Prevalence of the disorder in general population is estimated at 5 to
15%. Family history is positive in over 50% of idiopathic RLS patients which points to genetic basis of the disorder. The
characteristics of the secondary or acquired form of RLS are symptoms that start later in life as well as a rapid progres-
sion of the disease. On the other hand, idiopathic RLS more often starts at a younger age and the prognoses are better.
Over twenty disorders and conditions are brought in connection with secondary RLS. Although the cause of primary
RLS is still unknown, there is a strong connection between central metabolism of iron as well as dopamine levels and
RLS manifestation. A differential diagnosis of RLS includes a wide specter of motor and sensory disorders. Diagnosis is
based on clinical features and the history of disease. To correctly diagnose idiopathic RLS one must first eliminate sec-
ondary causes of RLS and then also exclude any disorders with clinical features that mimic those of RLS. It has been es-
timated that some 20 to 25% of patients need pharmacological therapy. Best initial therapy is the application of nonergot
dopamine agonists. Anticonvulsants, benzodiazepines and opioides can be given to patients who are refractory to dopa-
minergic therapy, those suffering from RLS with emphasized painful sensory component and those with RLS connected
with insomnia
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Introduction
Restless legs syndrome (RLS) is the central nervous
system disorder characterized by an irresistible need to
move one’s legs or arms, less commonly. Such need is ac-
companied or caused by unpleasant sensations in the ex-
tremities, which mostly manifest themselves at rest.
Moving the extremities eases or removes the unpleasant
sensations altogether. It is common for the symptoms to
get worse in the evening, before going to sleep and during
the night, which has a direct negative influence on the
ability to fall asleep or to stay asleep.
For the first time in 1672 Thomas Willis, M.D., de-
scribed as a separate clinical entity a patient who would
today be diagnosed as suffering from RLS. Willis wrote in
the London Practice of Physick (1685): »...Wherefore to
some, when being in bed they betake themselves to sleep,
presently in the arms and legs. Leaping and contractions
of the tendons and so great a restlessness and tossing of
the members ensure, that the diseased are no more able
to sleep, than if they were in the place of the greatest tor-
ture...«. It was not until 1945 that a Swedish doctor
Karl-Axel Ekbom identified and described the syndrome
and presented it on eight different cases in his book
»Restless Legs«1. The syndrome is also known as the
»Ekbom syndrome«. Another important year in the his-
tory of RLS was 1982 when dopaminergics (DA) were in-
troduced as a form of therapy2, which is still a gold stan-
dard for treatment. The syndrome has been called differ-
ent names – »Asthenia Crurum Paraesthetica«, »Irrita-
ble Legs«, »Anxietas Tibiarum« – the most widely ac-
cepted term today is the »Restless Legs Syndrome«.
Epidemiology
In spite of great discrepancies in the results of epide-
miological studies conducted so far, RLS is considered
the most common movement disorder and among the
most frequent of all known disorders. It is also one of the
most common causes of insomnia which can lead to
chronic fatigue and reduced ability in performing daily
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activities. These are the reasons why RLS is no longer
considered to be only an important medical issue but a
socio-economical issue as well. The prevalence of RLS is
controversial. The data differ from one study to another,
and according to some research the prevalence is as high
as 30%. In many epidemiological studies making a diag-
nose of RLS was mostly based on fulfilling the four essen-
tial diagnostic features without taking into account the
differential diagnosis of RLS mimics, thus probably ex-
plaining high prevalence in some studies. Recently, Cam-
bridge-Hopkins diagnostic questionnaire for RLS (CH-
-RLSq) was developed with sensitivity and specificity of
87.2% and 94.4%3. It is the first validated self-completed
questionnaire that includes questions designed to ex-
clude conditions that imitate RLS, making the true prev-
alence lower than previously reported. In support to this
observation is finding that 16% of patients with other
disorders fulfilled four essential RLS features4. The larg-
est studies have suggested that the prevalence of RLS is
5–12% in general population with prevalence of the clini-
cally significant RLS being between 1–3%5,6.
According to our observational study, performed in
outpatient clinic of Department of Neurology, Zagreb
School of Medicine and University Hospital Center Zag-
reb, the prevalence of RLS in Croatian population is
high7. Questionnaire based on diagnostic criteria devel-
oped by the International Restless Legs Study Group was
used8. A survey included 500 subjects with various neu-
rological symptoms aged 21 to 71 years. A total of 79
(15.8%) examines answered positively, fulfilling criteria
for RLS. Idiopathic form of RLS was found in 74 (93%) of
them, while secondary form of RLS due to anemia, diabe-
tes mellitus and uremia was found in 5 (7%) subjects.
High percentage of newly diagnosed could be imputable
to specific population included in study, although our re-
sults do not differ from some other studies conducted
worldwide neither from our underway investigation in
general population.
The RLS is closely related to a sleeping disorder called
Periodic Limb Movement in Sleep (PLMS), condition
characterized by rhythmic extensions of a toe thumb and
the dorsiflexion of the ankle joint with periodic flexions
in a hip or knee. Approximately 85% of RLS patients
have PLMS9. Whether RLS and PLMS are separate clini-
cal entities or just two forms of the same disease remains
to be revealed.
Etiology and Pathophysiology
RLS can etiologically be divided into idiopathic (famil-
ial, hereditary) and secondary (acquired). The latter ma-
nifests itself as a consequence of other pathological activ-
ities. The main causes of the secondary RLS are kidney
failure/uremia, iron deficiency, neuropathy, pregnancy,
folic acid deficiency, drugs (antipsychotics/neuroleptics,
tricyclic antidepressants, calcium channel antagonists, an-
tihypertensive, selective serotonin reuptake inhibitors/
SSRIs, lithium, antiemetics with central effect, antihis-
tamines), injuries and diseases of the spinal cord and the
Parkinson’s disease (PD). According to the Winkelmann’s
study conducted on 300 RLS patients, 77% of them suf-
fered from the idiopathic form of the disorder10. The
characteristics of the secondary-acquired form of RLS
are that the symptoms appear at an older age and faster
progression in contrast to idiopathic form. Family history
tested positive in over 50% of the cases with the idio-
pathic form of RLS, but also in 10 to 15% of those with a
secondary/acquired form, suggesting a genetic basis un-
derlying the disorder. The real cause behind the RLS is
still unknown. Peripheral localization of symptoms had
indicated that the origin of the syndrome might have
been peripheral. However, recent studies have shown a
central dysfunction to be a more plausible solution. Akpi-
nar’s finding of the dramatic amelioration of RLS symp-
toms11 on DA replacement therapy led to general conclu-
sion that RLS was hypodopaminergic condition, similar
to PD. That postulate has recently been disallowed.
Most research on the RLS pathophysiology has focu-
sed on the DA and iron system. Several functional neuro-
imaging studies, using SPECT (single photon emission
computer tomography) and PET (positron emission to-
mography) techniques, have been conducted in order to
understand the role of the DA system. Two of the studies
have shown a reduction of presynaptic DA function12 as
well as reduced reuptake of DA within nucleus caudatus
and putamen13. However, other studies did not confirm
these findings. The studies which focused on postsynap-
tic DA function came up with more consistent results. The-
re is evidence for reduced binding potential of postsynap-
tic striatal D2 receptors14,15. Recent study that evaluated
dopamine transporter (DAT) binding potential using PET
techniques showed reduction of membrane-bound stria-
tal DAT, but not total cellular DAT in RLS patients16.
The main shortcoming of the studies conducted so far
is their focus primarily on nigrostriatal DA pathway
while disregarding the mesolimbic and diencephalo-spi-
nal DA systems that could, hypothetically speaking, be a
location for the primary disorder as well. The occurrence
of RLS following spinal anesthesia, or injuries and dis-
eases of the spinal cord, has been established in the
literature17. A possible explanation could be found in the
loss of the supraspinal inhibition resulting in the facilita-
tion of spinal flexor responses.
Iron and DA metabolism exhibit daily oscillations
marked with higher levels of elementary iron in serum at
noon and lower levels at midnight. That, and the fact
that iron deficiency is among the most frequent causes of
secondary RLS, creates fertile ground for new ideas and
research on the possible role of iron in RLS pathophy-
siology. The role of iron in the disorder was further em-
phasized when it became apparent that the levels of
ferritin in serum and the severity of clinical features in
RLS patients are inversely proportional. Low amounts of
ferritin are the best indicators of reduced iron reserves.
Normal levels of ferritin are not always indicators of re-
quired iron reserves since ferritin is known as a reactant
of the acute phase. It has been observed that people who
experienced the first symptoms of the disease later in life
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and whose family history is negative, had significantly
lower levels of ferritin in serum then those with a posi-
tive family history and those who experienced first onset
of symptoms at an earlier age18. Recent discoveries stron-
gly suggest that there are abnormalities of iron metabo-
lism in the brain of the RLS patients. Reduced amounts
of ferritin and elevated levels of transferring were found
in cerebrospinal fluid19. On the other hand, the magnetic
resonance imaging showed a reduced iron concentration
in putamen and substantia nigra in RLS patients20,21. In
their pioneer work, Allen and the coworkers examined
the brains of the deceased who suffered from RLS during
lifetime and compared their observations with healthy
control samples. They realized that the subjects who had
RLS while they were alive had lower levels of ferritin and
higher levels of transferrin. They also noticed that the
transferrin receptors expression on neuromelanin cells
was lowered in the above mentioned subjects22. The lat-
ter is interesting because the lower levels of iron should
in fact result in the increase of transferrin receptors ex-
pression. Whether the low levels of intracellular iron are
regulates the uptake athe cause for the impaired homeo-
static mechanism whichnd outlet of iron, has yet to be an-
swered. However, a strong connection between iron me-
tabolism and DA system has been established. Iron is a
cofactor for tyrosine hydroxylase (TH), an enzyme cru-
cial for the synthesis of DA. Being an integral part of the
DA receptors iron deficit alter DA transporter function-
ing and causes up to 50% reduction of D1 and D2 recep-
tors (as tested on mice)23,24. Moreover, iron has a role in
regulating Thy1 protein, which is present as a cell adhe-
sion molecule on DA neurons in high degree. Thy1 pro-
tein regulates vesicular release of monoamines, DA in-
cluded25. Animal models with iron deficiency have shown
a reduced expression of Thy1 molecule on DA neurons. It
can be assumed that the reduced levels of iron cause a re-
duction of DA transporters and DA receptors which, as a
consequence, results in the increase of DA production
and in the disruption of circadian DA rhythm. This leads
to an assumption that postsynaptic receptors cannot ad-
just adequately to such extreme variations in the circa-
dian rhythm, thus causing a considerable reduction of
DA stimulation during the phase of lower concentration
of DA, which in high degree coincides with the develop-
ment of symptoms of RLS26.
Two recent studies turned the new page in under-
standing the pathophysiology of RLS, both disallowing
the thesis of RLS being hypodopaminergic condition. Au-
topsy study of RLS patients found increased TH activity
in the substantia nigra and decreased D2 receptors in the
putamen27, while abnormally increased CFS 3-O-methyl-
dopa (3-OMD) in untreated RLS patients was found in
the second study28. Both results are indicative for abnor-
mally increased DA synthesis in contrast to previous
thinking. Taken together, RLS is now considered to be
hyperdopaminergic condition (increased TH and 3-OMD)
consequently leading to postsynaptic desensitization (de-
creased D2 receptors) that overcompensates during eve-
ning and night (circadian low DA activity).
The theory of genetic basis of the origin of RLS, which
arose due to epidemiological findings on familial fre-
quency of the disorder’s occurrence, is still being investi-
gated. The assumption is that inheritance is autosomal
dominant with high penetration, although there are so-
me exceptions. Six suspected loci on chromosomes have
been described so far. These are loci on the chromosomes
12q22-23.3 (RLS1), 14q13-21 (RLS2), 9p24-22 (RLS3),
2q33 (RLS4), 20p13 (RLS5) and 19p, with a recessive in-
heritance form in the first and the autosomal dominant
form in the rest of the cases. Desaultes and the associates
were the first to identify a potential locus for RLS on a
12q chromosome of a French-Canadian family29. It has
been assumed that the genetic product is neurotensin, a
neuropeptide functioning as a neuromodulator of DA
neurotransmission. The inheritance form is autosomal
recessive in this case. Bonati and the associates found a
potential locus on the chromosome 14q13-21 of the Ital-
ian family with a three generation history of RLS and
PLMS30. That is the first locus with an autosomal domi-
nant inheritance form. Third described locus for RLS
was the one on chromosome 9p24-2231. RLS4 locus was
located on a 2q chromosome and was identified in an iso-
lated population of southern Tyrol32. The fifth locus was
detected on the 20p13 chromosome of a French-Cana-
dian family33. The last suspected locus that was detected
is the one on the 19p chromosome34. Two recently pub-
lished genetic studies showed that there was a significant
connection between RLS and the intron variants of
MEIS 1 gene on the 2p chromosome35, mitogen-activated
protein kinases MAP2K5 and the transcription factor
LBXCOR1 on the 15q chromosome as well as BTBD9
gene on 6p chromosome36. The risks of manifestation of
RLS in patients with variation of BTBD9 gene is 50%.
More recently, novel RLS susceptibility loci on 2p14 and
16q12.1 have been identified, but their involvement in
pathogenesis of RLS remains to be elucidated37. In addi-
tion, variants within the NOS1 (nitric oxide synthase)
gene were suggested to have a role in the pathogenesis of
RLS38. Whether these observations can be linked to the
fact that the prevalence of cardiovascular diseases is hi-
gher in the individuals with RLS symptoms39 is yet to be
seen. Further research of NOmodulating agents and their
possible therapeutic effects represent a major challenge.
Making a correct analogy between different medical
conditions and the manifestation of the RLS is a substan-
tial problem since RLS pathophysiology is still unclear.
More than 20 different disorders are linked to secondary
RLS. The connection between iron deficiency and the
manifestation of RLS has already been discussed. Kidney
failure/uremia is among the most common causes of sec-
ondary RLS with prevalence of RLS in patients undergo-
ing dialysis of 20 to 57%. The studies regarding the possi-
ble differences between patients undergoing a hemo-
dialysis and those undergoing peritoneal dialysis have
not been conducted. Pathogenesis of the uremic RLS is
unknown. An important clinical feature of kidney failure
is anemia, which occurs due to endocrinal insufficiency
of kidneys (reduced erythropoietin synthesis), reduced
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iron absorption, increased iron loss via digestive system,
and shorter life cycle of erythrocytes. The results of most
of the studies did not make a connection between any of
the markers (urea, creatinine) of renal function and RLS.
In study conducted on 490 patients undergoing hemo-
dialysis, Takaki specified stress and hyperphosphatae-
mia as possible signs of RLS in dialysis patients40. Dialy-
sis patients, whose therapy includes Ca++ antagonists,
have a higher chance to develop RLS41. In some patient
with renal failure and concomitant RLS, renal transplan-
tation showed great improvement of RLS symptoms42. It
has been estimated that 15 to 30% of RLS patients suffer
from a mild to moderately severe neurophatic abnormal-
ity which can be proven with standard electrophysiolo-
gical testing or nerve biopsy. The RLS patients with con-
firmed neuropathic disturbances usually have an incon-
spicuous family history. Their first RLS symptoms begin
at an older age and reach their top intensity rapidly,
which separates their symptoms from those associated
with the idiopathic form of the disease. It has been no-
ticed that two forms of Hereditary Motor and Sensory
Neuropathy (HMSN), Charcot-Marie-Tooth (CMT) type
1 and type 2 show different inclinations toward the de-
velopment of RLS. 37% of patients with CMT type 2 ex-
hibited symptoms of RLS while none of the patients suf-
fering from CMT type1 demyelinating neuropathy sho-
wed symptoms similar to those of RLS43. Prevalence
study of different neuropathic diseases accompanying di-
abetes mellitus (DM), conducted on 800 DM patients,
showed statistically insignificant difference in RLS prev-
alence between the healthy control group and the group
with DM. However, the same study showed a signifi-
cantly higher percentage of RLS in patients with DM
type II then in those with DM type I44. Traumatic inju-
ries of spinal cord, spinal anesthesia, neoplastic pro-
cesses which spread to the spinal cord, demyelinating or
postinfectious lesions can enhance one’s chances to de-
velop RLS. Transient form of RLS was recorded in 8.7%
cases immediately after the spinal anesthesia had been
performed45. Symptoms of RLS are common in multiple
sclerosis (MS) patients as well. In prospective study by
Italian authors, the prevalence of RLS in MS patients
stood at 37% and patients with severe damage to cervical
part of their spinal cord had significantly higher risks of
developing RLS46. Pregnancy is a predisposing factor for
RLS development and RLS is thought to affect more
than 20% of pregnant women. Furthermore, women who
developed RLS during pregnancy had a 4-fold increased
risk of developing chronic RLS compared with women
who did not have RLS when pregnant47. Symptoms most
frequently occurred in the third trimester. There were no
significant differences in age of the pregnant women,
their body mass index, the duration of pregnancy, to-
bacco consumption, way of delivery, and the weight of the
baby in those who developed RLS symptoms and in those
that did not. However, it has been noted that the levels of
elementary iron and hemoglobin in serum were signifi-
cantly lower in pregnant women who had developed clin-
ical features of RLS48. Lee and the coworkers monitored
45 healthy women prior to conception, during pregnancy
and after the delivery. The prevalence of RLS grew from
0% prior to conception to 23% in the third trimester. It
was noted that pregnant women with developed clinical
features of RLS had low ferritin in serum prior to concep-
tion, as well as significantly lowered amounts of folates
during pregnancy. Since the symptoms persisted in only
one pregnant woman after the delivery, this too is the
case, just like after the spinal anesthesia, of a transient
form of RLS49. Folates are necessary for synthesis of DA
in CNS. 5-methylenetetrahydrofolate increases the pro-
duction of tetrahydrobiopterine which is a cofactor in TH
synthesis. An interesting fact is that tetrahydrobiopte-
rine has a circadian pattern of concentration in serum
with higher amounts in the morning and lower in the
evening. The connection between RLS and PD has been
established long ago. Both RLS and PD have a positive
reaction to application of DA. Abnormalities of DA sys-
tem through neuroimaging studies were established in
both disorders and they were both closely connected to
PLMS12,13,50. It is important to mention that the patients
suffering from RLS developed augmentation after levo-
dopa treatment51. Augmentation is a phenomenon simi-
lar to manifestation of motor fluctuations in PD patients
who were treated with levodopa as well. It is hard to eval-
uate the prevalence of RLS in PD patients because the
symptoms of RLS in PD patients are mostly short-lived
and passing and they can be easily mistaken for symp-
toms such as dystonia, akathisia, tremors and nocturnal
motor fluctuations. Approximately 20.8% of PD patients
have symptoms of RLS52. Of all predisposing factors for
the development of RLS in PD population, the role of low
levels of ferritin in serum is the only one that has been
confirmed. Frequent manifestation of RLS in patients
suffering from spinocerebellar ataxia (SCA) was obser-
ved by Abel53. Even though the results of some studies
say that the prevalence of RLS among rheumatoid ar-
thritis patients is 30%, nothing apart from severely lower
levels of ferritin in serum could explain the connection
between these conditions. Different drugs can cause RLS
directly or can exacerbate the already existent RLS. The
most commonly described drugs in this context are those
from the group of antipsychotics (neuroleptics) due to D2
DA receptors blockage. Antiemetics (except for dompe-
ridon) can also cause RLS, due to the blockage of central
DA receptors. Other drugs that can provoke RLS are
SSRIs, tricyclic antidepressants, lithium, antihistami-
nes, calcium channel antagonists, antihypertensives. The
latest epidemiological studies have brought RLS in con-
nection with social habits and economic status54,55. In-
creased body mass index has been related to RLS. The
few studies that examined the relations of blood pres-
sure, smoking and alcohol consumption to RLS either
found no relation or report controversial results.
Clinical Features
Based on clinical features, the symptoms of RLS can
be divided into sensory and motor. The patients com-
monly complain to their doctor about uncomfortable sen-
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sory sensations in legs, accompanied with a need to
move, although in some cases the first signs of RLS can
be sleep disorders. Upper extremities are involved in 50%
of cases but the most common location of sensory sensa-
tions is the area between the knee and the ankle joint.
The changes in the quality of sensations can be mani-
fested as paresthesia and dysesthesia. Patients use differ-
ent expression to describe their sensory symptoms: craw-
ling, creeping, itching, pins and needles, painful, »antsy«,
electrical, or uncomfortable. Some of the most creative
descriptions are a »toothache in legs« and »Elvis legs«.
Another major symptom of RLS is motor discomfort.
People who cannot stop moving their legs while sitting do
not necessarily have RLS. One of the main characteris-
tics of RLS is that moving results in easing or in complete
disappearance of uncomfortable sensations. Such move-
ments are rich in their diversity and they can manifest as
jerking and turning of legs and arms, stretching and flex-
ing, rubbing the legs against each other, walking up and
down. This is why patients with RLS either avoid or han-
dle poorly the »activities« that include staying still, such
as long plane journeys, trips to a theater or similar activi-
ties. A characteristic of RLS is worsening of symptoms at
rest, especially in the evening, prior to bedtime or during
the night. In typical cases, the symptoms reach their
peak between midnight and 4 am, and the biggest relief
comes between 6 am and noon. The fact that the symp-
toms get worse in the evening has a negative effect on
falling asleep process as well as on staying asleep, which
leads to chronic daytime exhaustion and fatigue. Accord-
ing to severity of clinical features, RLS can be divided
into a mild form (symptoms occur only occasionally ac-
companied with mild sleep disorders), moderately severe
to severe form (symptoms occur on daily basis and de-
mand treatment) and refractory form which does not
seem to respond well to daily DA therapy or it leads to
progression of symptoms.
The natural course of disease is typical. RLS is a
chronic condition which can occur at any age. An early
occurrence is a characteristic of the idiopathic, heredi-
tary form, while a later onset of the disease, followed by a
fast progression of symptoms, points to the secondary
form of the disease. The symptoms fluctuate at first but
become more frequent and severe in time. Over 90% of
RLS patients suffer from a sleeping disorder and RLS is
itself among the most common causes of insomnia. RLS
is combined with PLMS in 80% to 90% of cases. The
characteristic of that disorder are periodic flexions in
hips and knees and less often in wrists as well as dorsifle-
xions in the upper ankle joint and in toes. Polysomno-
graphic tests are used in order to make the diagnosis.
The movements occur in series of al least four in a row.
One such movement lasts from 0.5 to 5 seconds while the
frequency is every 5 to 90 seconds. The index (the num-
ber of PLMSs during one hour of sleep) larger then 5
during the course of the night is pathological. PLMS
movements should not be confused with the so called
»hypnic jerks« or irregular twitching of the whole body
or just the extremities during the falling asleep process.
It is hypothesized that also cognitive impairments
may occur56. In 60% of RLS patients the disease has a
progressive course, while in 40% of the cases the disease
manifests itself in a relapse-remitting form with remis-
sion phases of different longitudes. It is important to
stress out that a neurological examination of RLS pa-
tients does not show any deviations from normal, except
from a possible existence of neuropathy.
Diagnosis
Diagnose of RLS is based on clinical features. It is
easy to diagnose a patient with typical symptoms. How-
ever, it can be hard to make a diagnosis if the symptoms
are atypical or if RLS is joined with another movement
disorder. The criteria in making the RLS diagnosis have
been suggested by NIH (National Institute for Health)
work group8 and updated in 200355,57 (Table 1). They con-
sist of four essential criteria and three supportive fea-
tures, which can be used to confirm the diagnosis but are
not crucial for making the diagnosis in the first place. Be-
sides these diagnostic criteria, there are also associated
features furthermore contributing the correct diagnosis.
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TABLE 1
DIAGNOSTIC CRITERIA FOR RESTLESS LEGS SYNDROME
Essential
criteria
• An urge to move the legs, usually accompanied or caused by uncomfortable or unpleasant sensations in the legs
• The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or
sitting
• The urge to move or unpleasant sensations are partially or totally relieved by movement such as walking or
stretching, at least as long as the activity continues
• The urge to move or unpleasant sensations are worse in the evening or at night than during the day, or only oc-
cur in the evening or night
Associated
features
• Positive family history of RLS
• Positive response to dopaminergic drugs
• Periodic limb movements during wakefulness or sleep as assessed with polysomnography or leg activity devices
Supportive
clinical
features
• Positive family history of RLS
• Positive response to dopaminergic drugs
• Periodic limb movements during wakefulness or sleep as assessed
Clinical, laboratory and electro-physical tests are re-
quired in order to eliminate the secondary causes of RLS.
The presence of neuropathies can be confirmed by an
electromyography (EMG) or by an electroneurography
(ENG). In case of positive findings, thyroid function
must be tested, and the levels of folates, vitamin B12 and
sugar in blood must be determined. Electrolytic status,
urea, creatinine are the determinants of renal function
and are involved in the testing algorithm. Radiological
tests and neuroimaging tests have more of a scientific-re-
searching value than diagnostic value. Other tests that
can be helpful in RLS diagnostics are polysomnography,
actigraphy and the immobilization test. Polysomnography
(PSG) is an exceptionally important diagnostic method
defined as simultaneous recording of several physiologi-
cal functions that occur during sleep. EEG, surface EMG
are electroculogram are recorded simultaneously. It is
possible to perform a cardio-respiratory monitoring as
well. PSG is indispensable in differentiating PLMS from
other sleeping disorders (sleep apnea, nocturnal myo-
clony, delayed sleep-phase syndrome, and other). Acti-
graphy is used to detect muscular activity with an acti-
graph unit tied around the ankle joint. The main use of
actigraphy is to evaluate the effectiveness of therapy. The
immobilization test is used in diagnosing and evaluating
the severity of clinical features. It is performed 90 min-
utes prior to bedtime and it lasts for an hour. During that
time, the patient lies awake in the bed under the angle of
45°. The leg activity is measured with standard bilateral
electromyography (EMG) while electroencephalogram
(EEG) is recorded at the same time. Every five minutes
the patient rates the intensity of discomfort on a visual
analogous scale.
Differential Diagnosis
Differential diagnosis of RLS includes a wide specter
of motor and sensory disorders. In order to make a cor-
rect idiopathic RLS diagnosis, first the secondary causes
of RLS must be excluded and then any other disorders
who clinical features can imitate those of RLS. RLS is
most commonly confused with neuropathies, especially if
they occur simultaneously. The characteristics of both
disorders are paresthesias and dysesthesias and the dif-
ference is in daily rhythm of symptoms and the effect of
movements on sensory sensations. Symptoms in RLS pa-
tients get worse at rest and in the evening while move-
ment ameliorates them, which is not the case in neuropa-
thy patients. Polysomnographic testing can be helpful
because if PLMS is detected, it can be used to confirm
RLS diagnosis. Akathisia is a drug-induced movement
disorder which is characterized with inability to either
stand or sit still. Akathisia can be caused by medications
which block central DA receptors (neuroleptics, anti-
-emetics affecting the central nervous system). When
compared with RLS, symptoms of akathisia do not seem
to have a daily rhythm – motor discomfort lasts through-
out the day and can attack any body parts whereas sen-
sory sensations do not exist. Nocturnal cramping in legs
is characterized by painful sensations in legs and can im-
itate RLS clinical features with dysesthesias. RLS can
also be confused with myoclonus. They are unconscious,
involuntary, rapid twitches of one or a group of muscles
which can but do not have to cause movements. Targeted
case history and clinical examination are enough to dif-
ferentiate these to disorders. Diseases of blood vessels
like varicose veins or peripheral arterial stenosis can be
characterized by painful sensory sensations. Main differ-
ences in regards to RLS are worsening of symptoms
while moving and easing of the symptoms while resting.
Hyperpigmentation and trophic skin changes can also be
there. Numerous other syndromes (painful leg and mov-
ing toe syndrome, causalgia-dystonia syndrome, hypo-
tensive akathisia, arthritis) can partially overlap with
RLS clinical characteristics. Being familiar with essen-
tial criteria and supportive features can alleviate the dis-
cerning and recognizing of RLS and enable correct treat-
ment, which can subsequently help make the everyday
life of patients less uncomfortable and restless.
Treatment
The decision to start therapy is based on the severity
of symptoms and their influence on the general condition
of the patient. The assumption is that 20% to 25% of RLS
patients require pharmacological treatment58 (Table 2).
Nonpharmacological measures are favored in case of
mild RLS symptoms. Effective ones seem to include
avoiding drinking coffee, tea or alcohol prior to bedtime,
quitting cigarette-smoking, proper sleep hygiene with
regular going to sleep pattern, relaxation and concentra-
tion techniques, yoga, light to moderate physical activity
and warm or cold baths. Secondary RLS needs to be
treated etiologically. The most common causes of second-
ary RLS are uremia, anemia and pregnancy. In most of
the pregnancies the symptoms improve after delivery59.
Unlike kidney transplantation, dialysis does not remove
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TABLE 2
PHARMACOLOGIC TREATMENT OF RESTLESS LEGS
SYNDROME
Intermittent
RLS symptoms
• Dopamine agonists: ropinirole,
pramipexole (low dose if tolerated)
• Levodopa with decarboxylase inhibitor
• Mild to moderate strength opioid (co-
deine, tramadol)
• Sedative – hypnotics
Daily RLS
symptoms
• Dopamine agonists
• Anticonvulsants (gabapentin)
• Opioids
• Benzodiazepines (clonazepam)
Refractory RLS
symptoms
• Change to a different dopamine agonist
• Switch to an opioid or anticonvulsant
• Add a second medication, possibly with
reduced agonist dose
• High potency opioids for severe and re-
sistant case (methadone)
RLS in patients with chronic renal failure60. Levels of
ferritin in serum which are bellow 50 ng/ml call for com-
pensation. Intravenous iron application proved to be far
more efficient then oral preparations. Early and the asso-
ciates achieved almost 60% symptom regression in RLS
patients after intravenous application of 1000 mg of
iron61.
Four groups of medications have proved to be effec-
tive in relieving RLS symptoms60,62 (Table 3).
a) DA drugs: Akpinar’s discovery regarding the positive
effects of levodopa, led to a new era in treating and
understanding RLS. DA are the best studied group of
medications and they represent a first choice therapy.
Still, there are certain differences in characteristics
among different subcategories of DA. Levodopa with
dopa-decarboxylase inhibitor: one evening application
of levodopa/benserazid (100+25) has proven to suc-
cessfully eliminate nocturnal symptoms (PLMS re-
duction, sleep quality improvement) of the idiopathic
and of the secondary RLS as well. The disadvantages
are the short half-life of levodopa (1 to 3 hours). Due
to side-effects, the treatment principle can best be de-
scribed with »start low, go slow« phrase. Complica-
tions due to long-term use of all DA are augmenta-
tion, rebound phenomenon and wide spectrum of
impulse control disorder including binge eating, com-
pulsive shopping, pathological gambling, punding and
hypersexuality63. Augmentation phenomenon was re-
corded in 80% of patients who had been on levodopa
for periods longer than two months51. Augmentation
is clinically manifested by an increase in severity of
symptoms beyond the level at baseline. Latest diag-
nostic standards for determining the augmentation
phenomenon date from 2007 and the severity of aug-
mentation itself can be assessed with the assistance of
ASRS scale (Augmentation Severity Rating Scale)64,65.
It is a progressive condition that requires a change in
treatment regimen in severe cases. When augmenta-
tion occurs the dosage should be lowered and applied
in several intervals. There is also a possibility of intro-
ducing non-DA drugs in therapy58. Having no specifi-
cally designed trials to measure augmentation it is
hard to evaluate true rate of this complication66. In
addition, it remains to be explored whether genetic
predisposition for developing augmentation or protec-
tive haplotype exist. The rebound phenomenon has
first been described in 199367. It denotes the appari-
tion of RLS symptoms in second half of the night and
before morning, once the applied dose looses its effect.
It appears less often than augmentation and poses a
less severe clinical problem. The augmentation and
rebound phenomena are quite similar to motor fluctu-
ations that occur in PD patients who have been on
levodopa for years. Side-effects seem to be less fre-
quent when controlled-release form of levodopa is ap-
plied. DA agonists are considered to be best initial
therapy. Bromocriptine was the first DA used in RLS
treatment. Compared to levodopa, bromocriptine has
shown a similar effectiveness and more frequent side-
-effects. The drug that has been tested for longest
time is pergolide, a long-lasting ergotine-based DA re-
ceptor agonist. In a two year study 45% of patients on
pergolide did not exhibit any symptoms and 50% of
them experienced a moderate relief of symptoms. The
most frequent side-effects are those that occur in the
very beginnings of treatment (in 60% of patients)
such as nausea, vomiting, insomnia and constipation.
Augmentation manifested in 27% of patients and mo-
stly mildly disturbed clinical condition68. After re-
ports of the fibrous changes of heart valves induced by
ergots these drugs are avoided69,70. Based on clinical
evidence, estimation of treatment efficiency, severity
and frequency of side-effects, nonergot DA prami-
pexole and ropinirole are considered to be the best
possible initial therapy. When a dose of 0.375 to 0.75
mg of pramipexole is applied, the symptoms of RLS
are alleviated and those of PLMS reduced71. The drug
did not seem to affect certain parameters of sleep
quality (overall time spent sleeping, the number of
awakenings). Side-effects when the treatment began
(nausea, dizziness) are milder and transient. Around
5 to 10% of patients who use pramipexole for at least
six months develop augmentation. It develops more
often in patients with secondary RLS. But prami-
pexole is effective in patients who have developed
augmentation and levodopa tolerance. Ropinirole has
the same effect on RLS and PLMS symptoms as
pramipexole. The advantages of pramipexole and ro-
pinirole are reduction of daytime sleepiness and im-
provement in sleeping quality as well as quantity.
Other DA mentioned are apomorphine, rotigotine72
and lisuride73.
b) Anticonvulsants: when DA therapy fails, use of anti-
convulsants seems appropriate. They are also useful
in treatment of RLS with emphasized painful sensory
component. Compared to ropinirole, gabapentin (me-
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TABLE 3
DOSE RANGE OF COMMON MEDICATIONS FOR RESTLESS
LEGS SYNDROME
Drug class Dose range (mg)
Dopaminergics:
• levodopa
• pramipexole
• ropinirole
50–200
0.125–0.75
0.25–4
Opioids:
• codeine
• tramadol
• oxycodone
• methadone
15–120
50–400
5–20
5–40
Anticonvulsants:
• gabapentin 300–2.700
Sedative – hypnotics:
• clonazepam
• flunazepam
0.5–2
15–60
dium applied dose of 800 mg) has a similar effect on
sensomotoric RLS and PLMS symptoms74.
c) Sedative – hypnotics: clonazepam is used most fre-
quently. The doses from 0.5 to 2 mg significantly re-
duce PLMS. The drug can be an alternative to DA in
treating insomnia related RLS. Wider application of
benzodiazepines is limited due to numerous side-ef-
fects (daytime sleepiness, confusion, slower reactions,
substance tolerance and addiction).
d) Opioids: oxycodone and propoxyphene can be useful in
patients who are refractory to DA therapy as well as
in treating RLS patients with pronounced sleep disor-
der. The efficiency of methadone in patients resistant
to any other form of therapy has been noticed lately75.
Intrathecall morphin aplication has also been investi-
gated76. A wider use of opioids is limited due to nu-
merous side-effects.
Conclusion
RLS is one of most frequent cause of insomnia leading
to chronic fatigue and functional disability during the
day. To diagnose idiopathic RLS one must first eliminate
secondary causes of RLS and then also exclude any disor-
ders with clinical features that mimic those of RLS. The
correct diagnose is based on criteria set up by Interna-
tional Restless Legs Study Group which consist of four
obligatory essential criteria, three supportive and three
associated criteria which are used to confirm the diagno-
sis. Recently developed validated diagnostic question-
naire should be considered for use in future studies3.
RLS is nowadays addressed to DA system dysfunction.
This became evident when positive effect of DA therapy
was observed both in primary and secondary form. Desir-
able objective of this review is to educate not only neurol-
ogist but general practioners as well.
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SINDROM NEMIRNIH NOGU
S A @ E T A K
Kao jedan od naj~e{}ih uzroka nesanice, {to u kona~nici uzrokuje kroni~an zamor, neadekvatno obavljanje dnevnih
aktivnosti te ozbiljno naru{avanje kvalitete `ivota, RLS danas predstavlja ne samo va`an medicinski ve} i sociolo{ko-
-ekonomski problem. Prevalencija se u op}oj populaciji procjenjuje na 5–15%. Obiteljska anamneza pozitivna je u vi{e
od 50% oboljelih od idiopatskog RLS-a, {to upu}uje na genetsku podlogu ovog poreme}aja. Po~etak simptoma u starijoj
`ivotnoj dobi i brza progresija obilje`ja su sekundarnog-ste~enog oblika RLS-a, za razliku od idiopatskog RLS-a koji se
prezentira u mla|ih osoba i ima bolju prognozu. Vi{e od 20 poreme}aja i stanja dovodi se u vezu sa sekundarnim RLS-
-om. Iako se uzrok primarnog RLS-a ne zna, postoji veza izme|u sredi{njeg metabolizma `eljeza i razine dopamina s
pojavom RLS-a. Diferencijalna dijagnoza sindroma nemirnih nogu obuhva}a {irok spektar motornih i senzornih pore-
me}aja. Dijagnoza RLS-a se postavlja na temelju klini~ke slike i povijesti bolesti pri tome zadovoljavaju}i esencijalne i
pomo}ne kriterije. Ispravno postavljanje dijagnoze idiopatskog RLS-a zahtijeva u prvom redu isklju~ivanje sekundar-
nih uzroka RLS-a, a potom i poreme}aja koji svojom klini~kom slikommogu opona{ati RLS. Pretpostavlja se da 20–25%
oboljelih od RLS-a zahtijeva farmakolo{ko lije~enje. Najboljom po~etnom terapijom smatra primjena ne-ergotinskih
dopaminskih antagonista. Antiepileptici, benzodiazepini i opioidi mogu se primjeniti u bolesnika refraktornih na dopa-
minergi~ku terapiju, u RLS-u s nagla{enom bolnom senzornom komponentom te RLS-u povezanom s nesanicom. S
obzirom na u~estalost bolesti, mogu}nost dijagnosticiranja te djelotvornost lije~enja ne samo neurolozi i psihijatri ve} i
lije~nici primarne zdravstvene za{tite moraju biti upoznati s prepoznavanjem i lije~enjem ovog sindroma.
